{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T20:34:59Z","timestamp":1790714099773,"version":"4.1.0"},"reference-count":16,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.jaad.2023.06.024","type":"journal-article","created":{"date-parts":[[2023,6,19]],"date-time":"2023-06-19T20:49:47Z","timestamp":1687207787000},"page":"1031-1037","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Relatlimab\u2013nivolumab: A practical overview for dermatologists"],"prefix":"10.1016","volume":"89","author":[{"given":"Nikita","family":"Mullick","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinod E.","family":"Nambudiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7934","key":"10.1016\/j.jaad.2023.06.024_bib1","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41586-022-05368-8","article-title":"Neoadjuvant relatlimab and nivolumab in resectable melanoma","volume":"611","author":"Amaria","year":"2022","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.jaad.2023.06.024_bib2","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1158\/2326-6066.CIR-22-0057","article-title":"Preclinical characterization of relatlimab, a human LAG-3-blocking antibody, alone or in combination with nivolumab","volume":"10","author":"Thudium","year":"2022","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"10.1016\/j.jaad.2023.06.024_bib3","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJMoa2109970","article-title":"RELATIVITY-047 investigators. Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma","volume":"386","author":"Tawbi","year":"2022","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.jaad.2023.06.024_bib4","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1177\/10600280221131396","article-title":"Nivolumab\/relatlimab: a novel addition to immune checkpoint inhibitor therapy in unresectable or metastatic melanoma","volume":"57","author":"Phillips","year":"2023","journal-title":"Ann Pharmacother"},{"issue":"10","key":"10.1016\/j.jaad.2023.06.024_bib5","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1002\/cncr.34227","article-title":"Relatlimab plus nivolumab beneficial for previously untreated metastatic or unresectable melanoma","volume":"128","author":"O'Rourke","year":"2022","journal-title":"Cancer"},{"key":"10.1016\/j.jaad.2023.06.024_bib6","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.785091","article-title":"Immune checkpoint LAG3 and its ligand FGL1 in cancer","volume":"12","author":"Shi","year":"2022","journal-title":"Front Immunol"},{"issue":"8","key":"10.1016\/j.jaad.2023.06.024_bib7","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1007\/s40265-022-01723-1","article-title":"Nivolumab plus relatlimab: first approval","volume":"82","author":"Paik","year":"2022","journal-title":"Drugs"},{"issue":"10","key":"10.1016\/j.jaad.2023.06.024_bib8","first-page":"602","article-title":"Nivolumab and relatlimab as frontline therapy in advanced melanoma","volume":"20","author":"Khushalani","year":"2022","journal-title":"Clin Adv Hematol Oncol"},{"issue":"7","key":"10.1016\/j.jaad.2023.06.024_bib9","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1158\/2159-8290.CD-NB2021-0347","article-title":"LAG3-PD-1 combo impresses in melanoma","volume":"11","year":"2021","journal-title":"Cancer Discov"},{"issue":"suppl 15","key":"10.1016\/j.jaad.2023.06.024_bib12","article-title":"Initial efficacy of anti-lymphocyte activation gene-3 (anti\u2013LAG-3; BMS-986016) in combination with nivolumab (nivo) in pts with melanoma (MEL) previously treated with anti\u2013PD-1\/PD-L1 therapy","volume":"35","author":"Ascierto","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2023.06.024_bib13","first-page":"1","article-title":"Double trouble: immunotherapy doublets in melanoma-approved and novel combinations to optimize treatment in advanced melanoma","volume":"42","author":"Dimitriou","year":"2022","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"20","key":"10.1016\/j.jaad.2023.06.024_bib14","doi-asserted-by":"crossref","first-page":"4975","DOI":"10.3390\/cancers14204975","article-title":"LAG3-PD1 or CTLA4-PD1 inhibition in advanced melanoma: indirect cross comparisons of the CheckMate-067 and RELATIVITY-047 trials","volume":"14","author":"Zhao","year":"2022","journal-title":"Cancers"},{"issue":"21","key":"10.1016\/j.jaad.2023.06.024_bib16","doi-asserted-by":"crossref","first-page":"5184","DOI":"10.3390\/cancers14215184","article-title":"Trends in melanoma phase 3 clinical trials since 2010: is there hope for advanced melanoma therapies beyond approved treatment mechanisms?","volume":"14","author":"Kakish","year":"2022","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.jaad.2023.06.024_bib17","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1002\/cam4.5067","article-title":"Immune checkpoint inhibitors as first line in advanced melanoma: evaluating progression-free survival based on reconstructed individual patient data","volume":"12","author":"Ossato","year":"2022","journal-title":"Cancer Med"},{"issue":"17","key":"10.1016\/j.jaad.2023.06.024_bib18","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1056\/NEJMc2119768","article-title":"CTLA-4 blockade resistance after relatlimab and nivolumab","volume":"386","author":"Menzies","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2023.06.024_bib19","unstructured":"Ferris R. Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer. ClinicalTrials.gov Identifier: NCT04080804. Posted September 6, 2019."}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962223011775?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962223011775?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T23:26:45Z","timestamp":1759274805000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962223011775"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":16,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S0190962223011775"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2023.06.024","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Relatlimab\u2013nivolumab: A practical overview for dermatologists","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2023.06.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}